Ark Invest, led by Cathie Wood, has significantly increased its investment in gene-editing firms and companies involved in autonomous mobility. The firm has added approximately $8.8 billion to its holdings in CRISPR Therapeutics by purchasing 155,649 shares.
In contrast, Ark has reduced its stake in Tesla and the space-launch company Rocket Lab. The strategic shift reflects a focus on emerging technologies in the healthcare and transportation sectors.